Evidence map›Paper›PMID 8772124›Full record

ArticlePflugers Archiv : European journal of physiology1996

Blockade of epithelial Na+ channels by triamterenes - underlying mechanisms and molecular basis.

A E Busch, H Suessbrich, K Kunzelmann, A Hipper, R Greger, S Waldegger, E Mutschler, B Lindemann, F Lang

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Pflugers Archiv : European journal of physiology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02522650 (A Crossover Pilot Study of the Effect of Amiloride on Proteinuria in Patients With Proteinuric Kidney Disease), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02522650 phase4unknown statusnot on this mapstarted 2013, after this paper: background citation

A Crossover Pilot Study of the Effect of Amiloride on Proteinuria in Patients With Proteinuric Kidney Disease

TypeinterventionalSponsorGeorgetown UniversityRan2013 to 2021Enrolled30ConditionsProteinuriaArmsAmiloride, Triamterene
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 39 citations in OpenAlex.

  1. Epithelial NaComprehensive Physiology · 2024
    Review
  2. Review
  3. Article
  4. Article
  5. Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA Mismatch Repair Deficient Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Article
  6. Article
  7. Distal convoluted tubule.Comprehensive Physiology · 2015
    Review
  8. Article
  9. Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy.Proceedings of the National Academy of Sciences of the United States of America · 2000
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

A E BuschPhysiologisches Institut I, Eberhard-Karls-University Tübingen, Gmelinstrasse 5, D-72076 Tübingen, Germany.
H Suessbrich
K Kunzelmann
A Hipper
R Greger
S Waldegger
E Mutschler
B Lindemann
F Lang
University of Freiburg · DEUniversity of Tübingen · DEGoethe University Frankfurt · DESaarland University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The three subunits (alpha, beta, gamma) encoding for the rat epithelial Na+ channel (rENaC) were expressed in Xenopus oocytes, and the induced Na+ conductance was tested for its sensitivity to various triamterene derivatives. Triamterene blocked rENaC in a voltage-dependent manner, and was 100-fold less potent than amiloride at pH 7.5. At -90 mV and -40 mV, the IC50 values were 5 microM and 10 microM, respectively. The blockage by triamterene, which is a weak base with a pKa of 6.2, was dependent on the extracellular pH. The IC50 was 1 microM at pH 6.5 and only 17 microM at pH 8.5, suggesting that the protonated compound is more potent than the unprotonated one. According to a simple kinetic analysis, the apparent inhibition constants at -90 mV were 0.74 microM for the charged and 100.6 microM for the uncharged triamterene. The main metabolite of triamterene, p-hydroxytriamterene sulfuric acid ester, inhibited rENaC with an approximately twofold lower affinity. Derivatives of triamterene, in which the p-position of the phenylmoiety was substituted by acidic or basic residues, inhibited rENaC with IC50 values in the range of 0.1-20 microM. Acidic and basic triamterenes produced a rENaC blockade with a similar voltage and pH dependence as the parent compound, suggesting that the pteridinemoiety of triamterene is responsible for that characteristic. Expression of the rENaC alpha-subunit-deletion mutant, Delta278-283, which lacks a putative amiloride-binding site, induced a Na+ channel with a greatly reduced affinity for both triamterene and amiloride. In summary, rENaC is a molecular target for triamterene that binds to its binding site within the electrical field, preferably as a positively charged molecule in a voltage- and pH-dependent fashion. We propose that amiloride and triamterene bind to rENaC using very similar mechanisms.

Indexed as

Sodium Channel BlockersAmilorideAnimalsDiureticsEpitheliumHydrogen-Ion ConcentrationMathematicsMembrane PotentialsRatsTriamtereneXenopus laevisAmiloridedimethylaminohydroxypropoxytriamtereneDiureticshydroxytriamterene sulfate esterRPH 3048Sodium Channel BlockersTriamterene

Identifiers

PMID8772124
OpenAlexW2091051976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.